Manufacturing and developing human proteins from human plasma and cell lines for therapeutic use in immunotherapy, hematology, and critical care.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: December 2025
This analysis is not yet available in English. Please see the French version.
Leading organizations
Biowest
B
Production and distribution of animal and human sera, plasma, and related products for cell culture.
Astraveus
B
Development and commercialization of microfluidic technologies for cell therapy manufacturing, including integrated solutions for research and production.
SFRI
B
Manufacturing and international export of in vitro diagnostic instruments and reagents, specializing in human biological analysis in hematology, biochemistry, and immunology sectors.
Initiatives identified among leaders
Financement de la recherche et développement pour l'innovation
“Astraveus reçoit un financement de 7,1 millions d'...” - AstraveusDéveloppement de produits éco-conçus
“SFRI met en place une politique de gestion des don...” - SFRIRespect des règles environnementales
“Biowest produit des milieux de culture cellulaire ...” - Biowest61% of similar organizations communicate on CSR issues
+2323 initiatives collected from 100 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports